Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099136 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02099136: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02099136 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02099136, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This randomized clinical trial studies if celecoxib will prevent the damaging effects of sunburn in healthy volunteers. Exposure to ultraviolet light can induce erythema, sunburn or skin redness caused by inflammation. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers. Studying samples of skin in the laboratory from patients receiving ultraviolet-radiation before and after celecoxib treatment may help doctors learn more about the effects celecoxib has on cells.
Interventions
- PROCEDURE Biopsy
- OTHER Placebo
- DRUG Celecoxib
- PROCEDURE UV Light Therapy
- OTHER Imaging Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099136
The ClinicalTrials.gov registry entry for NCT02099136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT02099136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099136 about?
NCT02099136 is a clinical study titled "Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers". This randomized clinical trial studies if celecoxib will prevent the damaging effects of sunburn in healthy volunteers. Exposure to ultraviolet light can induce erythema, sunburn or skin redness caused by inflammation. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in h...
What is the current status of trial NCT02099136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1999-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT02099136?
The interventions under investigation include: Biopsy (PROCEDURE), Placebo (OTHER), Celecoxib (DRUG), UV Light Therapy (PROCEDURE), Imaging Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02099136?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.